Literature DB >> 17429401

Synthetic lethal screen identification of chemosensitizer loci in cancer cells.

Angelique W Whitehurst1, Brian O Bodemann, Jessica Cardenas, Deborah Ferguson, Luc Girard, Michael Peyton, John D Minna, Carolyn Michnoff, Weihua Hao, Michael G Roth, Xian-Jin Xie, Michael A White.   

Abstract

Abundant evidence suggests that a unifying principle governing the molecular pathology of cancer is the co-dependent aberrant regulation of core machinery driving proliferation and suppressing apoptosis. Anomalous proteins engaged in support of this tumorigenic regulatory environment most probably represent optimal intervention targets in a heterogeneous population of cancer cells. The advent of RNA-mediated interference (RNAi)-based functional genomics provides the opportunity to derive unbiased comprehensive collections of validated gene targets supporting critical biological systems outside the framework of preconceived notions of mechanistic relationships. We have combined a high-throughput cell-based one-well/one-gene screening platform with a genome-wide synthetic library of chemically synthesized small interfering RNAs for systematic interrogation of the molecular underpinnings of cancer cell chemoresponsiveness. NCI-H1155, a human non-small-cell lung cancer line, was employed in a paclitaxel-dependent synthetic lethal screen designed to identify gene targets that specifically reduce cell viability in the presence of otherwise sublethal concentrations of paclitaxel. Using a stringent objective statistical algorithm to reduce false discovery rates below 5%, we isolated a panel of 87 genes that represent major focal points of the autonomous response of cancer cells to the abrogation of microtubule dynamics. Here we show that several of these targets sensitize lung cancer cells to paclitaxel concentrations 1,000-fold lower than otherwise required for a significant response, and we identify mechanistic relationships between cancer-associated aberrant gene expression programmes and the basic cellular machinery required for robust mitotic progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429401     DOI: 10.1038/nature05697

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  214 in total

1.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

2.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 3.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

5.  Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Authors:  Elena V Sheveleva; Terry H Landowski; Betty K Samulitis; Geoffrey Bartholomeusz; Garth Powis; Robert T Dorr
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

6.  Targeting and extending the eukaryotic druggable genome with natural products.

Authors:  Hendrik Luesch; John B MacMillan
Journal:  Nat Prod Rep       Date:  2020-06-24       Impact factor: 13.423

7.  Alkylation sensitivity screens reveal a conserved cross-species functionome.

Authors:  David Svilar; Madhu Dyavaiah; Ashley R Brown; Jiang-bo Tang; Jianfeng Li; Peter R McDonald; Tong Ying Shun; Andrea Braganza; Xiao-hong Wang; Salony Maniar; Claudette M St Croix; John S Lazo; Ian F Pollack; Thomas J Begley; Robert W Sobol
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma.

Authors:  Wenyue Sun; Shaoyu Zhou; Steven S Chang; Thomas McFate; Ajay Verma; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 10.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.